Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14897838 | 0.87 | OPRM1 (0.37) | OPRM1OPRL1LMNATEAD1MEN1 | |
| SCHEMBL14879429 | 0.81 | S1PR5 (0.40) | OPRM1OPRL1LMNAMEN1KMT2A | |
| SCHEMBL14897551 | 0.80 | OPRM1 (0.40) | OPRM1OPRL1LMNATEAD1MEN1 | |
| SCHEMBL14879829 | 0.74 | OPRM1 (0.42) | OPRM1OPRL1LMNAMEN1KMT2A | |
| SCHEMBL14879682 | 0.72 | MAPT (0.31) | — | |
| SCHEMBL28127054 | 0.71 | TEAD1 (0.35) | LMNATEAD1MEN1KMT2ADRD2 | |
| SCHEMBL16249350 | 0.70 | LMNA (0.38) | LMNAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL894236 | 0.67 | MAPT (0.45) | LMNAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL14897365 | 0.65 | S1PR5 (0.42) | OPRM1OPRL1LMNAMEN1KMT2A | |
| SCHEMBL12292240 | 0.64 | CYP19A1 (0.36) | LMNATEAD1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768491-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2768491-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9266908-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140343019-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-11-20 | — | — | US | disclosed |
| US-20140343019-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-11-20 | — | — | US | disclosed |
| US-20140343019-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-11-20 | — | — | US | disclosed |
| EP-2768491-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | Mars, Incorporated (US) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013059437-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343019-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT1 | OPRM1 3505/4885OPRL1 3203/4885LMNA 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.